Literature DB >> 22284755

A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen.

Polly Gregor1, Q Daisy Huang, Humilidad F Gallardo, Teresa S Rasalan, Michael J Morris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22284755      PMCID： PMC3358358          DOI： 10.1016/j.clgc.2011.12.002

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  8 in total

Review 1.  Immunity against cancer: lessons learned from melanoma.

Authors:  A N Houghton; J S Gold; N E Blachere
Journal:  Curr Opin Immunol       Date:  2001-04       Impact factor: 7.486

2.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

3.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature.

Authors:  S S Chang; V E Reuter; W D Heston; N H Bander; L S Grauer; P B Gaudin
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

4.  T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer.

Authors:  M Mercader; B K Bodner; M T Moser; P S Kwon; E S Park; R G Manecke; T M Ellis; E M Wojcik; D Yang; R C Flanigan; W B Waters; W M Kast; E D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

5.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Authors:  Jianda Yuan; Sacha Gnjatic; Hao Li; Sarah Powel; Humilidad F Gallardo; Erika Ritter; Geoffrey Y Ku; Achim A Jungbluth; Neil H Segal; Teresa S Rasalan; Gregor Manukian; Yinyan Xu; Ruth-Ann Roman; Stephanie L Terzulli; Melanie Heywood; Evelina Pogoriler; Gerd Ritter; Lloyd J Old; James P Allison; Jedd D Wolchok
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

Review 6.  Spontaneous regression of metastases from melanoma: review of the literature.

Authors:  Louise Vennegaard Kalialis; Krzysztof T Drzewiecki; Helle Klyver
Journal:  Melanoma Res       Date:  2009-10       Impact factor: 3.599

7.  Identification of naturally processed helper T-cell epitopes from prostate-specific membrane antigen using peptide-based in vitro stimulation.

Authors:  Hiroya Kobayashi; Ryusuke Omiya; Benjamin Sodey; Mitsuru Yanai; Kensuke Oikawa; Keisuke Sato; Shoji Kimura; Satoru Senju; Yasuharu Nishimura; Masatoshi Tateno; Esteban Celis
Journal:  Clin Cancer Res       Date:  2003-11-01       Impact factor: 12.531

8.  A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

Authors:  Evan M Hersh; Steven J O'Day; John Powderly; Khuda D Khan; Anna C Pavlick; Lee D Cranmer; Wolfram E Samlowski; Geoffrey M Nichol; Michael J Yellin; Jeffrey S Weber
Journal:  Invest New Drugs       Date:  2010-01-16       Impact factor: 3.651
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.